Nexien Biopharma Inc
Nexien BioPharma, Inc. focuses on the formulation, development, and commercialization of cannabinoid-based pharmaceuticals, drug delivery systems, and related technologies for diseases, disorders, and medical conditions in the United States. The company was formerly known as Intiva BioPharma Inc. and changed its name to Nexien BioPharma, Inc. in September 2018. Nexien BioPharma, Inc. is based in … Read more
Nexien Biopharma Inc (NXEN) - Total Assets
Latest total assets as of March 2025: $8.29K USD
Based on the latest financial reports, Nexien Biopharma Inc (NXEN) holds total assets worth $8.29K USD as of March 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Nexien Biopharma Inc - Total Assets Trend (2017–2024)
This chart illustrates how Nexien Biopharma Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Nexien Biopharma Inc - Asset Composition Analysis
Current Asset Composition (June 2024)
Nexien Biopharma Inc's total assets of $8.29K consist of 100.0% current assets and 0.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 100.0% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2017–2024)
This chart illustrates how Nexien Biopharma Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Nexien Biopharma Inc's current assets represent 100.0% of total assets in 2024, an increase from 49.7% in 2017.
- Cash Position: Cash and equivalents constituted 100.0% of total assets in 2024, up from 31.4% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 39.0% in 2017.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Nexien Biopharma Inc Competitors by Total Assets
Key competitors of Nexien Biopharma Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
|
USA | $67.26 Billion |
|
Kamada
NASDAQ:KMDA
|
USA | $378.79 Million |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
Nexien Biopharma Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Nexien Biopharma Inc generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Nexien Biopharma Inc is currently not profitable relative to its asset base.
Nexien Biopharma Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.02 | 0.04 | 0.78 |
| Quick Ratio | 0.02 | 0.04 | 0.78 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-450.52K | $ -325.29K | $ -6.37K |
Nexien Biopharma Inc - Advanced Valuation Insights
This section examines the relationship between Nexien Biopharma Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 205.41 |
| Latest Market Cap to Assets Ratio | 1.69 |
| Asset Growth Rate (YoY) | -90.3% |
| Total Assets | $4.18K |
| Market Capitalization | $7.08K USD |
Valuation Analysis
Above Book Valuation: The market values Nexien Biopharma Inc's assets above their book value (1.69 x), reflecting positive investor sentiment about the company's future prospects.
Significant Asset Reduction: Nexien Biopharma Inc's assets decreased by 90.3% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Nexien Biopharma Inc (2017–2024)
The table below shows the annual total assets of Nexien Biopharma Inc from 2017 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-06-30 | $4.18K | -90.30% |
| 2023-06-30 | $43.13K | -65.36% |
| 2022-06-30 | $124.52K | +387.52% |
| 2021-06-30 | $25.54K | +12.09% |
| 2020-06-30 | $22.79K | -92.67% |
| 2019-06-30 | $310.67K | -75.58% |
| 2018-06-30 | $1.27 Million | +64.45% |
| 2017-06-30 | $773.69K | -- |